drugset / Trial / NCT05515120
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
RandomizedParallel-groupSingle-blindTreatment
Summary
Venous thromboembolism affects around 10 million people per year worldwide, however, despite its high incidence, there is no systematic review or randomized trial focused on the treatment of patients with recurrent deep vein thrombosis (DVT) and/or or pulmonary embolism (PE) during anticoagulant treatment. The objective was to compare the use of Rivaroxaban plus Aspirin versus Acenocoumarol in patients with recurrent venous thromboembolism treated with rivaroxaban.
Timeline
- Start
- 2021-01-03
- Primary completion
- 2022-01-09
- Completion
- 2022-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 300 mg | — |
| Comparator | Rivaroxaban | Other / unclassified | 20 mg | — |
| Comparator | acenocoumarol | Unknown | — | Oral |